Retour aux projets

17994.1 PFLS-LS

Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

Résumé

Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

Textes supplémentaires

Abstract

More than 300¿000 patients are diagnosed with pancreatic ductal adenocarcinoma (PDA) each year with a median survival of only 2-17 months. 82C2 is a novel human derived monoclonal antibody with proven efficacy in mouse carcinoma models, with potential to prolong survival for PDA patients with improved efficacy compared to current standard of care. This CTI project application seeks support to advance 82C2 into clinical trials to treat PDA patients by 2019.

Participants

Chad Brokopp

Wirtschaftspartner

Mabimmune Diagnostics AG Chad Brokopp Wagistrasse 13 8952 Schlieren ZH CH

Simon Hoerstrup

Kontaktperson

Simon_Philipp.Hoerstrup@usz.ch

Universität Zürich Simon Hoerstrup Rämistrasse 100 8091 Zürich ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2015-07-31
Date de fin
2017-10-31
Coûts totaux approuvés
CHF 671174.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%